← Back to Search

Anti-helminthic

Niclosamide for Coronavirus (RESERVOIR Trial)

Phase 2
Waitlist Available
Research Sponsored by First Wave Bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 43
Awards & highlights

RESERVOIR Trial Summary

This trial is testing two different treatments for COVID-19 in adults with gastrointestinal infection. The trial is double-blind, meaning neither the participants nor the researchers will know which treatment the participants are receiving.

Eligible Conditions
  • Coronavirus

RESERVOIR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 43
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to day 43 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Fecal RNA virus Clearance
SAEs
Safety Laboratory Tests including CBC, BUN, blood sugar, electrolytes
+1 more
Secondary outcome measures
Clinical Severity Score
Time to Resolution of Diarrhea

Side effects data

From 2021 Phase 2 trial • 73 Patients • NCT04399356
21%
Nausea
9%
Skin rash
6%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Control Group
Niclosamide- Experimental Group

RESERVOIR Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NiclosamideExperimental Treatment1 Intervention
Niclosamide tablets 400 mg 3 times daily for 14 days
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo tablets 3 times daily for 14 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Niclosamide
2017
Completed Phase 3
~2280

Find a Location

Who is running the clinical trial?

First Wave Bio, Inc.Lead Sponsor
6 Previous Clinical Trials
108 Total Patients Enrolled
AzurRx BioPharma, Inc.Lead Sponsor
2 Previous Clinical Trials
68 Total Patients Enrolled
First Wave BioPharma, Inc.Lead Sponsor
6 Previous Clinical Trials
108 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
2021. "Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04858425.
~42 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top